See Bull Run's current company pages for Sun Pharmaceutical Industries and Divi's Laboratories. The wider peer universe is available on Bull Run's Pharmaceuticals sector page.

Sun generated approximately 4.9 times Divi's quarterly revenue.

But Sun generated only about 3.5 times Divi's EBITDA and 3.2 times Divi's PAT. The difference reflects Divi's unusually rich Q1 product mix and the fundamentally different economics of custom synthesis.

Q1 FY27 financial scorecard

Sun Pharma is increasingly a specialty-medicines company

This is one of the most important facts in Sun Pharma's transformation.

The company was historically known primarily as an Indian branded-generics and US generics manufacturer.

Today, more than one-fifth of sales comes from Innovative Medicines.

Its portfolio includes brands and programmes across dermatology, ophthalmology and oncology-related areas.

Products such as Ilumya, Cequa and Odomzo give Sun a different economic profile from a conventional generic-drug manufacturer.

Why specialty medicines can command higher economic value

A successful specialty product can benefit from:

• clinical differentiation;
• patent or exclusivity protection;
• specialist physician relationships;
• branded pricing;
• lower direct generic competition during exclusivity;
• international expansion;
• indication extensions.

The trade-off is much higher development risk.

A molecule can consume years of R&D and regulatory investment before commercial revenue begins.

Clinical trial failure can destroy much of that invested value.

Divi's generally does not take this same molecule-development risk when acting as a manufacturing partner.

India remains Sun's largest geographic profit engine

India formulations generated approximately ₹5,475 crore in Q1 FY27.

Sales grew 16% year on year and represented 36.1% of consolidated sales.

Sun's domestic market share increased from around 8.2% to 8.5% over the year.

The company remains India's largest pharmaceutical company by domestic market share.

Growth during Q1 was led by cardiovascular, central nervous system, gastroenterology and orthopaedic therapies.

A branded domestic franchise is strategically valuable

Indian prescription medicines do not behave exactly like US commodity generics.

Doctors often prescribe brands by name.

Successful companies build large field forces, physician relationships and therapy leadership over decades.

That can create pricing power and recurring prescription demand.

Sun's domestic franchise therefore provides a stable earnings base that can finance innovative R&D.

The US business shows why generic exposure still matters

US formulations generated US$427 million in Q1 FY27 and declined 9.7% year on year.

Innovative Medicines continued growing, but weakness in the generic portfolio—particularly products such as lenalidomide—offset part of that growth.

This demonstrates why Sun is trying to increase specialty exposure.

US generic profits can be highly sensitive to:

• competition;
• price erosion;
• product exclusivity;
• FDA approvals;
• customer concentration;
• manufacturing compliance.

Divi's avoids the commercial-branding problem

Divi's does not need thousands of pharmaceutical sales representatives promoting its APIs to doctors.

Its customers are pharmaceutical companies.

The company competes through:

• chemistry expertise;
• process efficiency;
• large manufacturing scale;
• regulatory compliance;
• supply reliability;
• backward integration;
• ability to handle complex molecules.

That produces a very different cost structure.

Custom Synthesis drove Divi's extraordinary Q1

Custom Synthesis is effectively a contract-manufacturing partnership for specific customer molecules.

The customer may own the drug and commercial brand while Divi's develops and manufactures intermediates or APIs at scale.

Once a manufacturing process is validated and embedded in a customer's regulatory filing, switching suppliers can become complicated.

This can create long-duration customer relationships.

Why Custom Synthesis can produce very high margins

Custom projects often involve:

• complex chemistry;
• proprietary manufacturing processes;
• dedicated capacity;
• customer confidentiality;
• regulatory validation;
• high purity requirements;
• long product lifecycles.

The economics can therefore be much better than a highly competitive generic API sold to many customers.

That is visible in Divi's 40.8% Q1 EBITDA margin.

Do not automatically annualise Divi's 40.8% margin

This is essential for valuation.

If investors multiply one unusually strong quarter by four, they can overestimate normalized earnings.

Custom Synthesis campaigns may be produced and shipped in large batches.

Generic API pricing can also change.

Currency movements and inventory effects can influence margins.

The more useful test is whether Divi's can sustain high-30s operating profitability across a multi-year period while new dedicated projects ramp.

Three major custom-synthesis projects are approaching commercialisation

Divi's management indicated that three major capex programmes were nearing completion during Q1.

Validation work was already underway and some validation material had been shipped to customers.

But validation material is not the same as full commercial revenue.

Customers must still complete their own qualification and, where necessary, receive regulatory approvals.

This creates a potentially powerful growth pipeline but also introduces timing uncertainty.

Divi's is building a peptide opportunity

Peptide manufacturing is becoming increasingly important because of global demand for complex peptide medicines, including metabolic and other therapies.

Divi's has been investing in solid-phase peptide synthesis capability and related backward integration.

The opportunity is attractive because peptide manufacturing requires specialised chemistry, purification and scale-up expertise.

That raises technical barriers relative to conventional commodity APIs.

Contrast media adds another specialised growth vertical

Divi's has also invested in contrast-media products, including iodine-based molecules.

Management has discussed commercial activity with existing customers and additional long-term programmes moving toward qualification.

These products can diversify the business beyond traditional generic APIs.

Sun is taking much more R&D risk

Sun Pharma spent approximately ₹826 crore on R&D in Q1 FY27, equal to 5.4% of sales.

About 30% of the R&D spend related to Innovative Medicines.

Its clinical-stage pipeline included programmes in psoriatic arthritis, oncology, diabetes and other indications.

These investments can produce very high future returns if products succeed.

They can also generate years of expense without guaranteed commercial revenue.

Divi's R&D is more manufacturing-led

Divi's research model focuses much more heavily on process chemistry, scale-up, manufacturing efficiency and customer programmes.

That reduces clinical-development risk.

But it introduces customer dependence.

If a customer's drug fails clinically, loses market share or changes sourcing strategy, Divi's can lose future manufacturing volume even if its own execution was excellent.

The risk maps are therefore completely different

Sun's global diversification is much greater

Sun's Q1 sales mix was approximately:

• 36% India;
• 27% US;
• 19% Emerging Markets;
• 14% Rest of World;
• 4% API and other revenues.

This geographic diversity reduces dependence on one pharmaceutical market.

But the US remains important enough that generic pressure can still affect consolidated growth.

Divi's is more dependent on global innovator manufacturing cycles

Divi's customer base is export-heavy and closely linked to global pharmaceutical development and supply chains.

That provides access to high-value international demand.

It also means foreign exchange, geopolitical logistics and global customer inventory decisions can affect quarterly performance.

Sun has a much larger balance-sheet war chest

Sun reported a net cash position of approximately US$3.4 billion in its Q1 earnings presentation.

This gives the company flexibility for:

• R&D;
• product acquisitions;
• licensing;
• manufacturing expansion;
• larger strategic transactions.

The proposed Organon acquisition is an example of the much larger capital-allocation decisions Sun is now willing to pursue.

The Organon transaction can materially change Sun's future profile

Sun signed definitive documents for the proposed Organon transaction in April 2026.

Organon shareholders approved the proposed acquisition in July.

Sun's Q1 presentation indicated an expected closing around Q4 FY27, subject to remaining conditions and approvals.

Until closing, the companies remain independent.

The acquisition could materially increase Sun's global commercial scale, but it also creates integration and financing risk.

Divi's balance sheet is structurally simpler

Bull Run's current database shows Divi's with essentially zero debt-to-equity.

That simplicity is attractive in a capital-intensive manufacturing business.

The company can fund large projects without the leverage profile seen in many CDMO peers.

However, large capex still depresses capital returns until utilisation rises.

ROCE is much closer than the margin difference suggests

Divi's EBITDA margin was almost twelve percentage points higher than Sun's in Q1.

Yet ROCE differs by only about one percentage point.

That illustrates why margin alone cannot determine business quality.

Large manufacturing assets and capex consume capital.

Sun's lower EBITDA margin still produces a strong return because branded products, commercial infrastructure and specialty medicines can generate significant profit without requiring proportionally larger manufacturing assets for every incremental rupee of revenue.

Valuation reverses the apparent growth advantage

Divi's trades at approximately 70% higher trailing earnings multiple than Sun Pharma.

Its price-to-book multiple is also more than twice Sun's.

The market is paying for:

• faster growth;
• very high Q1 margins;
• Custom Synthesis expansion;
• peptide manufacturing;
• new dedicated customer programmes;
• low leverage.

Sun's lower P/E reflects its more mature base, slower current growth and continued exposure to US generics.

But the lower multiple also gives Sun a materially smaller valuation hurdle.

Divi's has already rerated strongly

Bull Run's September snapshot shows Divi's up approximately 50% over one year.

Sun Pharma is up around 23%.

Divi's therefore enters the next phase with much stronger market expectations embedded in the share price.

Future returns need Custom Synthesis programmes to convert successfully rather than relying only on further rerating.

Sun's valuation is unusual given its specialty exposure

Sun's Innovative Medicines portfolio now contributes around 22% of sales.

Yet its trailing P/E remains below Divi's.

If innovative-product growth accelerates while India maintains mid-teens growth, the company's mix can gradually become more valuable.

The counterweight is acquisition risk and the continued volatility of US generics.

What must Sun Pharma prove?

• Innovative Medicines should remain a double-digit growth engine.
• India formulations need to keep gaining market share.
• US generic weakness should not overwhelm specialty growth.
• R&D programmes need successful regulatory milestones.
• Semaglutide and complex products should create durable revenue.
• The proposed Organon transaction must be financed and integrated prudently.
• ROCE should remain healthy through larger capital allocation.

What must Divi's Laboratories prove?

• Custom Synthesis growth must persist beyond an unusually strong Q1.
• The 40.8% EBITDA margin should not collapse when product mix normalises.
• Dedicated capex programmes need customer qualification and commercial ramp.
• Peptide investment must translate into profitable commercial volumes.
• Generic API pricing pressure should remain manageable.
• Raw-material and solvent inflation needs effective pass-through.
• New capex should preserve 20%-plus ROCE.

What could make Divi's outperform Sun Pharma?

A sustained Custom Synthesis super-cycle.

If global innovators outsource more complex manufacturing and Divi's new dedicated programmes ramp successfully, revenue can grow materially faster than the broader pharmaceutical market.

At 30%-plus normalized margins, even moderate incremental sales can create powerful profit growth.

What could make Sun Pharma outperform Divi's?

Specialty-product compounding combined with valuation discipline.

Sun starts at a much lower P/E.

If Innovative Medicines keep growing in the low-to-mid teens, India remains strong and US generics stabilise, Sun can produce high absolute earnings growth without requiring another valuation rerating.

Which has the stronger current margin?

Divi's Laboratories.

Its Q1 FY27 EBITDA margin was approximately 40.8% versus Sun Pharma at 28.9%.

However, Divi's quarterly mix can be more volatile.

Which has the stronger current commercial franchise?

Sun Pharma.

Its India leadership, 100-plus-country presence and Innovative Medicines portfolio give it much broader direct access to patients and prescribers.

Which has the purer manufacturing exposure?

Divi's Laboratories.

Investors get direct exposure to APIs, intermediates and complex Custom Synthesis without the same level of commercial-brand and clinical-development risk.

Which has the stronger valuation?

Sun Pharma.

Its roughly 38.8x P/E is substantially below Divi's around 66x despite similar current ROCE.

Which is better: Sun Pharma or Divi's Laboratories?

Sun Pharma currently offers the stronger valuation-adjusted diversified pharmaceutical franchise. It has nearly five times Divi's revenue, a global specialty portfolio, India's leading branded business, a large net-cash position and a substantially lower earnings multiple.

Divi's Laboratories currently offers the stronger high-margin manufacturing growth story. Q1 revenue grew 28%, PAT grew 66%, Custom Synthesis represented about 60% of revenue and the EBITDA margin exceeded 40%.

The central question is durability.

Sun's earnings are more diversified but grow from a much larger base.

Divi's can grow faster, but quarterly Custom Synthesis mix and project timing can create greater volatility.

At September 2026 valuations, Sun has the lower valuation hurdle and broader earnings architecture; Divi's has the faster growth and higher margin profile but requires more future execution to justify a roughly 66x P/E.

Frequently asked questions